Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Torr

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Thrombosis Research|December 1, 1993
Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from plateletsS R Torr-Brown, B E Sobel
Coronary Artery Disease|January 1, 1996
Antiplatelet effects of urokinase and their clinical implicationsS R Torr-Brown, B E Sobel
British Journal of Pharmacology|February 1, 1984
Evidence that the positive inotropic effects of the alkylxanthines are not due to adenosine receptor blockadeM G Collis, J R Keddie, S R Torr
Thrombosis Research|November 15, 1991
The dependence of activation of platelets by a plasminogen activator on the evolution of thrombin activityS R Torr, P R Eisenberg, B E Sobel
Journal of the American College of Cardiology|April 1, 1992
"Plasminogen steal" and clot lysisS R Torr, D A Nachowiak, S Fujii, et al.
Coronary Artery Disease|July 1, 1994
Lack of degradation of antithrombin III by tissue-type plasminogen activator or plasminS R Torr-Brown, D Nachowiak, S Fujii, et al.
Thrombosis Research|July 15, 1990
The nature of interactions between tissue-type plasminogen activator and plateletsS R Torr, K J Winters, S A Santoro, et al.
Journal of the American College of Cardiology|July 1, 1993
Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and plateletsN A Prager, S R Torr-Brown, B E Sobel, et al.
Journal of the American College of Cardiology|December 1, 1991
Inhibition of cyclic flow variations and reocclusion after thrombolysis in dogs by a novel antagonist of platelet-activating factorS R Torr, E J Haskel, P F VonVoigtlander, et al.
Circulation|August 1, 1991
Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitorE J Haskel, S R Torr, K C Day, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Thrombosis Research|December 1, 1993
Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from plateletsS R Torr-Brown, B E Sobel
Coronary Artery Disease|January 1, 1996
Antiplatelet effects of urokinase and their clinical implicationsS R Torr-Brown, B E Sobel
British Journal of Pharmacology|February 1, 1984
Evidence that the positive inotropic effects of the alkylxanthines are not due to adenosine receptor blockadeM G Collis, J R Keddie, S R Torr
Thrombosis Research|November 15, 1991
The dependence of activation of platelets by a plasminogen activator on the evolution of thrombin activityS R Torr, P R Eisenberg, B E Sobel
Journal of the American College of Cardiology|April 1, 1992
"Plasminogen steal" and clot lysisS R Torr, D A Nachowiak, S Fujii, et al.
Coronary Artery Disease|July 1, 1994
Lack of degradation of antithrombin III by tissue-type plasminogen activator or plasminS R Torr-Brown, D Nachowiak, S Fujii, et al.
Thrombosis Research|July 15, 1990
The nature of interactions between tissue-type plasminogen activator and plateletsS R Torr, K J Winters, S A Santoro, et al.
Journal of the American College of Cardiology|July 1, 1993
Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and plateletsN A Prager, S R Torr-Brown, B E Sobel, et al.
Journal of the American College of Cardiology|December 1, 1991
Inhibition of cyclic flow variations and reocclusion after thrombolysis in dogs by a novel antagonist of platelet-activating factorS R Torr, E J Haskel, P F VonVoigtlander, et al.
Circulation|August 1, 1991
Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitorE J Haskel, S R Torr, K C Day, et al.
Pageof 1